哮喘预防:干预靶点
全球约3亿人受哮喘影响,预计到2025年可能再增1亿患者。本文总结已研究的哮喘预防干预措施,指出停滞特应性进展、调节微生物组、预防呼吸道病毒感染及通过膳食补充剂减少毒素/污染物暴露的策略效果有限,可能因哮喘异质性及遗传与环境因素不同所致。未来预防可能包括基于遗传变异、哮喘表型或生物标志物的更个性化方法,并识别了正在进行的临床试验。
要点
- 全球约3亿人患哮喘,2025年可能再增1亿,预防策略需求迫切。
- 现有预防策略(停滞特应性进展、调节微生物组、预防病毒感染、膳食补充剂减少暴露)效果有限。
- 未来方向为基于遗传变异、表型或生物标志物的个性化预防。
核心结论
- 现有哮喘预防策略效果有限,未来需更个性化方法。
研究设计与样本
- 总结已研究的哮喘预防干预措施并识别正在进行的临床试验。
主要发现
- 停滞特应性进展、调节微生物组、预防呼吸道病毒感染及膳食补充剂减少毒素/污染物暴露的策略效果有限。
- 哮喘异质性及不同遗传和环境因素影响可能解释预防策略效果有限。
- 未来预防可能包括基于遗传变异、哮喘表型或生物标志物的个性化方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 300 million people worldwide are estimated to be affected by asthma, and the number of patients affected is growing exponentially-with potential for an additional 100 million people affected by the condition by 2025. With this increasing burden of disease, there is high motivation to discover effective prevention strategies. Strategies aimed at stalling the atopic progression, modifying the microbiome, preventing respiratory viral infections, and reducing the impact of toxin/pollutant exposure through dietary supplements have had limited success in the prevention of asthma. This is likely because asthma is heterogenous and is influenced by different genetic and environmental factors. Genes underlie a predisposition to asthma and allergic sensitization, whereas exposure to allergens, respiratory infections, and pollution may modify asthma pathogenesis and the variation in severity seen among individuals. Future advances in asthma prevention may include a more personalized approach: genetic variations among susceptible individuals with distinct asthma phenotypes or different biomarkers of disease may help individualize prevention strategies and render them more . In this article, we summarize interventions that have been studied for the prevention of asthma and identify some of the clinical trials that are actively underway in asthma prevention.
引用
- Maciag MC, Phipatanakul W. Prevention of Asthma: Targets for Intervention. Chest. 2020. PMID: 32330461. doi:10.1016/j.chest.2020.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。